Related Pages for MAXHEALTH
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
MAXHEALTH
Related News - MAXHEALTH
Max Healthcare Institute: Plans to Expand by Around 8,300 Beds, With Approximately 4,000 Beds Expected to Be Added Within the Next 3-4 Years.
17 Aug 2026 10:24 PM
Max Healthcare Institute: Plans to Expand by Around 8,300 Beds, With Approximately 4,000 Beds Expected to Be Added Within the Next 3-4 Years.
Max Healthcare: CLSA on Max Healthcare Maintains Outperform with Target Price of ₹1,160 as strong revenue growth, aggressive bed expansion plans, entry into medical education, and long-term growth visibility outweigh near-term margin pressure from new capacities and acquisitions.
17 Aug 2026 08:57 AM
Max Healthcare: CLSA on Max Healthcare Maintains Outperform with Target Price of ₹1,160 as strong revenue growth, aggressive bed expansion plans, entry into medical education, and long-term growth visibility outweigh near-term margin pressure from new capacities and acquisitions.
Max Healthcare: JPMorgan on Max Healthcare Maintains Overweight with Target Price of ₹1,300 as mid-teen revenue and EBITDA growth, healthy occupancy, improving profitability outlook, and a strong balance sheet support future expansion.
17 Aug 2026 08:57 AM
Max Healthcare: JPMorgan on Max Healthcare Maintains Overweight with Target Price of ₹1,300 as mid-teen revenue and EBITDA growth, healthy occupancy, improving profitability outlook, and a strong balance sheet support future expansion.
Max Healthcare: UBS on Max Healthcare Maintains Buy with Target Price of ₹1,300 as Q1 exceeded estimates, brownfield capacity additions are expected to drive growth, and planned medical college investments offer attractive long-term returns.
17 Aug 2026 08:57 AM
Max Healthcare: UBS on Max Healthcare Maintains Buy with Target Price of ₹1,300 as Q1 exceeded estimates, brownfield capacity additions are expected to drive growth, and planned medical college investments offer attractive long-term returns.
Max Health: Anticipates Increase In Net Debt By FY27 Because Of Capital Expenditure Plans, Currently At INR 23.84 Billion As Of June 30.
14 Aug 2026 11:58 AM
Max Health: Anticipates Increase In Net Debt By FY27 Because Of Capital Expenditure Plans, Currently At INR 23.84 Billion As Of June 30.
Max Healthcare: Gets Approval To Establish Medical Colleges And Institutions.
13 Aug 2026 02:38 PM
Max Healthcare: Gets Approval To Establish Medical Colleges And Institutions.
MAX HEALTHCARE: Q1 CONS NET PROFIT 3.2B RUPEES VS 3.1B (YOY); EST 4B
13 Aug 2026 02:28 PM
MAX HEALTHCARE: Q1 CONS NET PROFIT 3.2B RUPEES VS 3.1B (YOY); EST 4B
MAX HEALTHCARE: Q1 REVENUE 23.7B RUPEES VS 20.2B (YOY)
13 Aug 2026 02:28 PM
MAX HEALTHCARE: Q1 REVENUE 23.7B RUPEES VS 20.2B (YOY)
MAX HEALTHCARE: Q1 EBITDA 5.98B RUPEES VS 5.23B (YOY) || Q1 EBITDA MARGIN 25.3% VS 25.8% (YOY)
13 Aug 2026 02:29 PM
MAX HEALTHCARE: Q1 EBITDA 5.98B RUPEES VS 5.23B (YOY) || Q1 EBITDA MARGIN 25.3% VS 25.8% (YOY)
Max Healthcare Institute: NCLT Delays Hearing On BRS Capital Two Pte. Limited's Petitions Against Kalinga Hospital Ltd.; Next Hearing Set For August 4, 2026.
24 Jul 2026 12:12 PM
Max Healthcare Institute: NCLT Delays Hearing On BRS Capital Two Pte. Limited's Petitions Against Kalinga Hospital Ltd.; Next Hearing Set For August 4, 2026.
Max Healthcare: Citi maintains Buy on Max Healthcare Institute with a Target Price of ₹1,240, citing an attractive entry point after an 18% correction, supported by 20% EBITDA CAGR through FY26–30E from new capacity, strong balance sheet, expected revenue acceleration from FY27–28 via capacity ramp-up, oncology recovery and better payer mix, with CGHS oncology pricing reversal as upside optionality.
18 Jun 2026 08:55 AM
Max Healthcare: Citi maintains Buy on Max Healthcare Institute with a Target Price of ₹1,240, citing an attractive entry point after an 18% correction, supported by 20% EBITDA CAGR through FY26–30E from new capacity, strong balance sheet, expected revenue acceleration from FY27–28 via capacity ramp-up, oncology recovery and better payer mix, with CGHS oncology pricing reversal as upside optionality.
Max Healthcare: CCI Orders End to 10-Year-Old Anti-Competition Case Involving 12 Hospitals. - CNBC TV18
22 May 2026 11:52 AM
Max Healthcare: CCI Orders End to 10-Year-Old Anti-Competition Case Involving 12 Hospitals. - CNBC TV18
Max Healthcare: Plans Major Expansion With 3,500 New Beds Over Three Years - Conference Call Update
22 May 2026 11:02 AM
Max Healthcare: Plans Major Expansion With 3,500 New Beds Over Three Years - Conference Call Update
MAX HEALTHCARE: Q4 CONS NET PROFIT 3.4B RUPEES VS 3.2B (YOY) || Q4 REVENUE 21.4B RUPEES VS 19.1B (YOY)
21 May 2026 04:37 PM
MAX HEALTHCARE: Q4 CONS NET PROFIT 3.4B RUPEES VS 3.2B (YOY) || Q4 REVENUE 21.4B RUPEES VS 19.1B (YOY)
MAX HEALTHCARE: Q4 EBITDA 6B RUPEES VS 5.1B (YOY) || Q4 EBITDA MARGIN 28.30% VS 26.8% (YOY)
21 May 2026 04:38 PM
MAX HEALTHCARE: Q4 EBITDA 6B RUPEES VS 5.1B (YOY) || Q4 EBITDA MARGIN 28.30% VS 26.8% (YOY)
Max Healthcare: Acquires About 58.28% Stake In Kalinga Hospital For ₹297.97 Crore, Making It A Subsidiary.
18 May 2026 08:35 PM
Max Healthcare: Acquires About 58.28% Stake In Kalinga Hospital For ₹297.97 Crore, Making It A Subsidiary.
Max Healthcare: Faces ₹55.20 Crore GST Claim For Possible Extra ITC, Starts Rectification And Appeal Process
31 Dec 2025 08:05 AM
Max Healthcare: Faces ₹55.20 Crore GST Claim For Possible Extra ITC, Starts Rectification And Appeal Process
